Don’t Miss Out on the Latest Updates.
Subscribe to Our Newsletter Today!
Parkinson's Disease (PD) is a progressive movement disorder of the nervous system that includes parts of your brain, spinal cord, and a complex network of nerves.
A recent groundbreaking study of the phase-II trial has revealed that a common cough syrup can potentially slow cognitive decline in Parkinson's Disease patients who develop Parkinson's Disease Dementia (PDD).
Researchers during a 12-month-long study at the Lawson Research Institute found that a cough syrup called Ambroxol has shown a promising result in stabilising psychiatric symptoms, improving cognitive functions, and protecting against brain damage in genetically at-risk participants.
The study, titled "Ambroxol as a Treatment for Parkinson Disease Dementia", which is now published in the JAMA Neurology, compared the results of Ambroxol with a placebo among 55 participants with PDD, administering high-dose Ambroxol (525 1,050 mg/day).
While the primary and secondary results showed similar results, the participant on the placebo experienced "worsening in neuropsychiatric symptoms, whereas those receiving ambroxol remained stable."
Ambroxol is a drug typically used in the treatment of respiratory diseases linked with viscid or excessive mucus.
PDD is a condition that develops after being diagnosed with Parkinson's Disease. People with Parkinson's Disease show signs of symptoms like a decline in thinking and reasoning skills.
Cleveland Clinic explains, "Parkinson's Disease is a neurodegenerative brain condition that mainly affects your movements, causing tremors, slowed movements (bradykinesia) and other issues. But it can also affect the parts of your brain responsible for mental functions. This is when dementia may develop."
Symptoms of Parkinson's Disease may vary from person to person. However, below are some of the most common signs, according to the Centres for Disease Control and Prevention (CDC):